Table 3.
Genes synergistically upregulated by the combination of 9.2s RNA and CL264.
| Gene name | Unigene ID | Gene symbol | Transcript level (fold over nonstimulated control) | |||
|---|---|---|---|---|---|---|
| 9.2s RNA | CL264 | 9.2s RNA + CL264 | Synergistic increase | |||
| CD69 molecule | Hs.208854 | CD69 | 2.4 | 6.1 | 64.2 | 7.6 |
| BCL2-related protein A1 | Hs.227817 | BCL2A1 | 2.7 | 22.2 | 96.6 | 3.9 |
| baculoviral IAP repeat containing 3 | Hs.127799 | BIRC3 | 1.2 | 6.4 | 25.6 | 3.4 |
| RALBP1 associated Eps domain containing 2 | Hs.186810 | REPS2 | 1.0 | 2.4 | 10.3 | 3.1 |
| Interferon, beta 1, fibroblast | Hs.93177 | IFNB1 | 1.6 | 1.9 | 10.8 | 3.1 |
| Suppressor of tumorigenicity 20 | Hs.729127 | ST20 | 1.3 | 4.8 | 18.5 | 3.0 |
| Chemokine (C-C motif) ligand 2 | Hs.303649 | CCL2 | 0.6 | 41.4 | 126.0 | 3.0 |
| CD44 molecule | Hs.502328 | CD44 | 1.5 | 4.3 | 17.5 | 3.0 |
| Early growth response 3 | Hs.534313 | EGR3 | 2.1 | 3.3 | 15.9 | 2.9 |
| Tubulin tyrosine ligase-like family | Hs.520554 | TTLL2 | 1.1 | 3.1 | 11.9 | 2.8 |
| Oligonucleotide/oligosaccharide-binding fold containing 2A | Hs.591610 | OBFC2A | 1.7 | 12.4 | 38.6 | 2.7 |
| Interleukin 6 (interferon, beta 2) | Hs.654458 | IL-6 | 0.9 | 4.9 | 14.7 | 2.6 |
| Nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha | Hs.81328 | NFKBIA | 1.6 | 6.2 | 19.6 | 2.5 |
| MIR155 host gene (non-protein-coding) (MIR155HG), noncoding RNA. | N/A | MIR155HG | 1.5 | 1.9 | 8.1 | 2.4 |
| Chemokine (C-C motif) ligand 1 | Hs.72918 | CCL1 | 2.4 | 15.6 | 41.8 | 2.3 |
| RasGEF domain family, member 1B | Hs.591696 | RASGEF1B | 1.1 | 3.3 | 10.2 | 2.3 |
| CD70 molecule | Hs.501497 | CD70 | 1.4 | 6.1 | 16.5 | 2.2 |
| G protein-coupled receptor 183 | Hs.784 | GPR183 | 1.0 | 2.6 | 7.8 | 2.2 |
| ADAM metallopeptidase with thrombospondin type 1 motif, 10 | Hs.657508 | ADAMTS10 | 1.0 | 1.9 | 6.1 | 2.1 |
| ADAM metallopeptidase domain 19 | Hs.483944 | ADAM19 | 2.4 | 3.6 | 12.6 | 2.1 |
| FSHD region gene 2 family, member C | Hs.274541 | FRG2C | 0.8 | 1.1 | 4.1 | 2.1 |
| Interleukin 23, alpha subunit p19 | Hs.98309 | IL-23A | 1.6 | 7.8 | 19.4 | 2.1 |
| EF-hand calcium binding domain 3 | Hs.152670 | EFCAB3 | 1.0 | 1.3 | 4.8 | 2.1 |
| Neutrophil cytosolic factor 2 | Hs.587558 | NCF2 | 1.8 | 3.8 | 11.5 | 2.1 |
| Interleukin 1, beta | Hs.126256 | IL-1B | 1.0 | 7.3 | 17.0 | 2.1 |
| Nuclear receptor subfamily 4, group A, member 3 | Hs.279522 | NR4A3 | 1.4 | 3.1 | 9.4 | 2.1 |
| Tumor necrosis factor, alpha-induced protein 3 | Hs.211600 | TNFAIP3 | 1.5 | 3.5 | 10.2 | 2.1 |
| Regulator of G-protein signaling 1 | Hs.75256 | RGS1 | 1.7 | 3.5 | 10.7 | 2.0 |
| Serum/glucocorticoid regulated kinase 1 | Hs.510078 | SGK1 | 0.5 | 1.8 | 4.8 | 2.0 |
| v-rel reticuloendotheliosis viral oncogene homolog | Hs.631886 | REL | 1.1 | 2.4 | 6.7 | 2.0 |
| Immediate early response 3 | Hs.76095 | IER3 | 0.8 | 4.3 | 9.9 | 1.9 |
| Nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, zeta | Hs.319171 | NFKBIZ | 1.3 | 2.7 | 7.8 | 1.9 |
| Chemokine (C-C motif) ligand 4-like 2 | Hs.661942 | CCL4L2 | 2.0 | 21.0 | 43.9 | 1.9 |
| Interleukin 18 receptor 1 | Hs.469521 | IL-18R1 | 2.5 | 6.9 | 17.9 | 1.9 |
| Interleukin 8 (IL8) | Hs.624 | IL-8 | 1.8 | 2.4 | 7.9 | 1.9 |
| CASP8 and FADD-like apoptosis regulator | Hs.390736 | CFLAR | 1.5 | 2.2 | 6.8 | 1.9 |
| pim-2 oncogene | Hs.496096 | PIM2 | 0.8 | 3.0 | 7.1 | 1.8 |
| Spermidine/spermine N1-acetyltransferase 1 | Hs.28491 | SAT1 | 1.6 | 3.6 | 9.5 | 1.8 |
| Interleukin 4 induced 1 | Hs.574492 | IL-4I1 | 1.2 | 4.0 | 9.4 | 1.8 |
| Chemokine (C-X-C motif) ligand 10 | Hs.632586 | CXCL10 | 1.6 | 5.8 | 13.1 | 1.8 |
| Solute carrier family 29 (nucleoside transporters), member 2 | Hs.569017 | SLC29A2 | 1.4 | 3.4 | 8.6 | 1.8 |
| Long intergenic non-protein-coding RNA 173, noncoding RNA. | N/A | LINC00173 | 1.8 | 3.2 | 8.8 | 1.8 |
| Mitogen-activated protein kinase kinase kinase 8 | Hs.432453 | MAP3K8 | 1.1 | 4.1 | 9.1 | 1.8 |
| Signal transducer and activator of transcription 5A | Hs.437058 | STAT5A | 0.8 | 1.9 | 4.6 | 1.7 |
| ADP-ribosylation factor-like 5B | Hs.25362 | ARL5B | 1.5 | 3.1 | 7.9 | 1.7 |
| Ninjurin 1 | Hs.494457 | NINJ1 | 0.9 | 3.4 | 7.3 | 1.7 |
| Wingless-type MMTV integration site family, member 10A | Hs.121540 | WNT10A | 1.2 | 5.8 | 11.6 | 1.6 |
| B cell translocation gene 1, antiproliferative | Hs.255935 | BTG1 | 1.5 | 2.6 | 6.7 | 1.6 |
| Fascin homolog 1, actin-bundling protein (Strongylocentrotus purpuratus) | Hs.118400 | FSCN1 | 0.5 | 1.6 | 3.5 | 1.6 |
| CD83 molecule | Hs.595133 | CD83 | 1.7 | 5.2 | 11.4 | 1.6 |
| Platelet-derived growth factor alpha polypeptide | Hs.535898 | PDGFA | 1.4 | 2.3 | 6.1 | 1.6 |
| Transcription factor EC | Hs.125962 | TFEC | 0.6 | 3.1 | 6.1 | 1.6 |
| CD40 molecule, TNF receptor superfamily member 5 | Hs.472860 | CD40 | 1.0 | 4.1 | 8.4 | 1.6 |
| POU class 2 homeobox 2 | Hs.654420 | POU2F2 | 0.6 | 3.2 | 6.2 | 1.6 |
| Nuclear receptor coactivator 7 | Hs.171426 | NCOA7 | 1.6 | 2.7 | 6.8 | 1.6 |
| Zinc finger protein 36, C3H type-like 1 | Hs.85155 | ZFP36L1 | 1.3 | 2.0 | 5.1 | 1.6 |
| Solute carrier family 7, member 11 | Hs.390594 | SLC7A11 | 1.4 | 2.2 | 5.7 | 1.6 |
| FSHD region gene 2 | Hs.626907 | FRG2 | 1.1 | 1.3 | 3.7 | 1.5 |
| Homo sapiens microRNA miR-146 stem-loop | N/A | hsa-mir-146a | 1.1 | 3.7 | 7.3 | 1.5 |
| Homo sapiens microRNA miR-21 stem-loop | N/A | hsa-mir-21 | 1.6 | 1.7 | 5.1 | 1.5 |
| BTB (POZ) domain containing 19 | Hs.632400 | BTBD19 | 0.8 | 1.7 | 3.9 | 1.5 |
| ELOVL fatty acid elongase 6 | Hs.412939 | ELOVL6 | 1.1 | 1.7 | 4.2 | 1.5 |
CAL-1 cells were treated as described above (see Table 1). The table lists specific genes synergistically upregulated by the combination of 9.2s RNA and CL264. Genes in the costimulated group with expressions being upregulated 1.5-fold of the sum induced by the ligands 9.2s RNA and CL264 alone were defined as being synergistically regulated.